Therapeutic pyrazolyl thienopyridines
    1.
    发明授权
    Therapeutic pyrazolyl thienopyridines 有权
    治疗性吡唑并噻吩并吡啶类

    公开(公告)号:US07964612B2

    公开(公告)日:2011-06-21

    申请号:US11871311

    申请日:2007-10-12

    IPC分类号: A61K31/4365 C07D495/04

    摘要: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

    摘要翻译: 本发明提供式I化合物及其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 5,R 6和R 7具有本说明书中定义的任何值及其药学上可接受的盐, 可用作治疗TGF-bgr介导的病症,包括癌症和纤维化疾病的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。

    Therapeutic pyrazolyl thienopyridines
    2.
    发明授权
    Therapeutic pyrazolyl thienopyridines 有权
    治疗性吡唑并噻吩并吡啶类

    公开(公告)号:US08455512B2

    公开(公告)日:2013-06-04

    申请号:US13112520

    申请日:2011-05-20

    IPC分类号: A61K31/4365 C07D495/04

    摘要: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

    摘要翻译: 本发明提供式I化合物及其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 5,R 6和R 7具有在本说明书中定义的任何值及其药学上可接受的盐, 可用作治疗TGFbeta介导的病症(包括癌症和纤维化疾病)的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。

    THERAPEUTIC PYRAZOLYL THIENOPYRIDINES
    3.
    发明申请
    THERAPEUTIC PYRAZOLYL THIENOPYRIDINES 有权
    治疗性吡唑并噻唑啉酮

    公开(公告)号:US20140031385A1

    公开(公告)日:2014-01-30

    申请号:US13864457

    申请日:2013-04-17

    IPC分类号: C07D495/04

    摘要: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

    摘要翻译: 本发明提供式I化合物及其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 5,R 6和R 7具有本说明书中定义的任何值及其药学上可接受的盐, 可用作治疗TGFbeta介导的病症(包括癌症和纤维化疾病)的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。

    3,5-di-tetriary-4-butyl-4-hydroxyphenyloxy- or tioalkylene
N-hydroxyamides, N-hydroxythioamides, N-hydroxyureas, and
N-hydroxythioureas as 5-lipoxygenase inhibitors
    6.
    发明授权
    3,5-di-tetriary-4-butyl-4-hydroxyphenyloxy- or tioalkylene N-hydroxyamides, N-hydroxythioamides, N-hydroxyureas, and N-hydroxythioureas as 5-lipoxygenase inhibitors 失效
    3,5-二 - 叔丁基-4-羟基苯氧基 - 或二亚烷基N-羟基酰胺,N-羟基硫代酰胺,N-羟基脲和N-羟基硫脲作为5-脂氧合酶抑制剂

    公开(公告)号:US5442111A

    公开(公告)日:1995-08-15

    申请号:US705480

    申请日:1991-05-24

    申请人: James B. Kramer

    发明人: James B. Kramer

    IPC分类号: C07C335/40 C07C335/12

    CPC分类号: C07C335/40

    摘要: 3,5-Di-tertiary-butyl-4-hydroxyphenyloxy- or thioalkylene N-hydroxyamides, N-hydroxythioamides, N-hydroxyureas, and N-hydroxythioureas, and pharmaceutically acceptable base salts thereof, pharmaceutical compositions thereof, and methods of manufacture thereof are described. The compounds are said to be selective, potent 5-lipoxygenase inhibitors and useful in treating, for example, inflammatory and allergic conditions.

    摘要翻译: 3,5-二叔丁基-4-羟基苯氧基 - 或硫代亚烷基N-羟基酰胺,N-羟基硫代酰胺,N-羟基脲和N-羟基硫脲,及其药学上可接受的碱盐,其药物组合物及其制备方法 描述。 据说这些化合物是选择性的,有效的5-脂氧合酶抑制剂,可用于治疗,例如炎性和过敏性疾病。